Physician profile
James E Rice
NPI 1083651863
$718.13
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $52.40 · 2021: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $220.03 | 2019-2021 | |
| Depuy Synthes Sales INC. | $142.64 | 2019 | |
| Medtronic USA, INC. | $131.74 | 2019 | |
| Biodelivery Sciences International, INC. | $75.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.34 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.93 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.35 | 2019-2020 | |
| Djo, LLC | $16.93 | 2019 | |
| Mdd US Operations, LLC | $14.03 | 2019 | |
| Zyla Life Sciences, INC. | $13.89 | 2019 | |
| Daiichi Sankyo INC. | $13.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.